These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15290343)

  • 1. The multifaceted role of transglutaminase in neurodegeneration: review article.
    Karpuj M; Steinman L
    Amino Acids; 2004 Jul; 26(4):373-9. PubMed ID: 15290343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Critical role of transglutaminase and other stress proteins during neurodegenerative processes.
    Caccamo D; Currò M; Condello S; Ferlazzo N; Ientile R
    Amino Acids; 2010 Feb; 38(2):653-8. PubMed ID: 19960212
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue transglutaminase: a novel pharmacological target in preventing toxic protein aggregation in neurodegenerative diseases.
    Wilhelmus MM; van Dam AM; Drukarch B
    Eur J Pharmacol; 2008 May; 585(2-3):464-72. PubMed ID: 18417122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine.
    Karpuj MV; Becher MW; Springer JE; Chabas D; Youssef S; Pedotti R; Mitchell D; Steinman L
    Nat Med; 2002 Feb; 8(2):143-9. PubMed ID: 11821898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
    Martin A; Giuliano A; Collaro D; De Vivo G; Sedia C; Serretiello E; Gentile V
    Amino Acids; 2013 Jan; 44(1):111-8. PubMed ID: 21938398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Transglutaminase and neurodegenerative diseases].
    Liu Z; Zeng J; Zeng S; Tang B; Wang J
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2015 Aug; 32(4):562-6. PubMed ID: 26252108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New target against inflammatory diseases: transglutaminase 2.
    Kim SY
    Arch Immunol Ther Exp (Warsz); 2004; 52(5):332-7. PubMed ID: 15507874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurodegeneration and peroxidases.
    Everse J; Coates PW
    Neurobiol Aging; 2009 Jul; 30(7):1011-25. PubMed ID: 18053617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced transglutaminase-catalyzed protein aggregation is observed in the presence of creatine using sedimentation velocity.
    Burguera EF; Love BJ
    Anal Biochem; 2006 Mar; 350(1):113-9. PubMed ID: 16445883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transglutaminases - possible drug targets in human diseases.
    Gentile V; Cooper AJ
    Curr Drug Targets CNS Neurol Disord; 2004 Apr; 3(2):99-104. PubMed ID: 15078184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GTP is required to stabilize and display transamidation activity of transglutaminase 2.
    Jeon JH; Cho SY; Kim CW; Shin DM; Kweon JC; Choi KH; Park SC; Kim IG
    Biochem Biophys Res Commun; 2002 Jun; 294(4):818-22. PubMed ID: 12061780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transglutaminase is linked to neurodegenerative diseases.
    Muma NA
    J Neuropathol Exp Neurol; 2007 Apr; 66(4):258-63. PubMed ID: 17413316
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transglutaminase-catalyzed reactions responsible for the pathogenesis of celiac disease and neurodegenerative diseases: from basic biochemistry to clinic.
    Martin A; Romito G; Pepe I; De Vivo G; Merola MR; Limatola A; Gentile V
    Curr Med Chem; 2006; 13(16):1895-902. PubMed ID: 16842200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transglutaminase-catalyzed crosslinking in neurological disease: from experimental evidence to therapeutic inhibition.
    Hoffner G; André W; Vanhoutteghem A; Souès S; Djian P
    CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):217-31. PubMed ID: 19811443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lysine-rich histone (H1) is a lysyl substrate of tissue transglutaminase: possible involvement of transglutaminase in the formation of nuclear aggregates in (CAG)(n)/Q(n) expansion diseases.
    Cooper AJ; Wang J; Pasternack R; Fuchsbauer HL; Sheu RK; Blass JP
    Dev Neurosci; 2000; 22(5-6):404-17. PubMed ID: 11111157
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetic analysis of the interaction of tissue transglutaminase with a nonpeptidic slow-binding inhibitor.
    Case A; Stein RL
    Biochemistry; 2007 Jan; 46(4):1106-15. PubMed ID: 17240993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Aggregation and toxicity of the proteins with polyQ repeats].
    Leźnicki P
    Postepy Biochem; 2005; 51(2):215-22. PubMed ID: 16209359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenesis of inclusion bodies in (CAG)n/Qn-expansion diseases with special reference to the role of tissue transglutaminase and to selective vulnerability.
    Cooper AJ; Sheu KF; Burke JR; Strittmatter WJ; Gentile V; Peluso G; Blass JP
    J Neurochem; 1999 Mar; 72(3):889-99. PubMed ID: 10037459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transglutaminase inhibition as a possible therapeutical approach to protect cells from death in neurodegenerative diseases.
    Iannaccone M; Serretiello E; De Vivo G; Martin A; Stefanile A; Titta F; Gentile V
    Recent Pat CNS Drug Discov; 2013 Aug; 8(2):161-8. PubMed ID: 23688272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transglutaminase as the agent of neurodegenerative diseases due to polyglutamine expansion.
    Kahlem P; Green H; Djian P
    Pathol Biol (Paris); 1998 Nov; 46(9):681-2. PubMed ID: 9885815
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.